Barclays PLC Puma Biotechnology, Inc. Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Barclays PLC holds 108,653 shares of PBYI stock, worth $560,649. This represents 0.0% of its overall portfolio holdings.

Number of Shares

108,653

Previous 108,653 -0.0%

Holding current value

$560,649

Previous $372,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$2.74 - $3.72 $69,574 - $94,458	25,392 Added 30.5%	108,653 $372,000
Q1 2025 May 15, 2025	SELL	$2.76 - $3.88 $14,202 - $19,966	-5,146 Reduced 5.82%	83,261 $247,000
Q4 2024 Feb 13, 2025	BUY	$2.42 - $3.39 $25,134 - $35,208	10,386 Added 13.31%	88,407 $270,000
Q3 2024 Nov 15, 2024	BUY	$2.25 - $4.03 $104,332 - $186,871	46,370 Added 146.5%	78,021 $199,000
Q2 2024 Aug 14, 2024	BUY	$2.92 - $5.83 $41,834 - $83,526	14,327 Added 82.7%	31,651 $104,000
Q4 2023 Feb 15, 2024	SELL	$2.23 - $4.49 $4,373 - $8,804	-1,961 Reduced 10.17%	17,324 $75,000
Q3 2023 Nov 07, 2023	BUY	$2.63 - $4.09 $5,115 - $7,955	1,945 Added 11.22%	19,285 $50,000
Q2 2023 Aug 03, 2023	BUY	$2.6 - $3.58 $109 - $150	42 Added 0.24%	17,340 $61,000
Q4 2022 Feb 13, 2023	SELL	$2.12 - $5.08 $78,041 - $187,004	-36,812 Reduced 68.03%	17,298 $73,000
Q3 2022 Nov 03, 2022	SELL	$2.27 - $3.84 $6,710 - $11,351	-2,956 Reduced 5.18%	54,110 $129,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.3 $8,596 - $17,298	-5,242 Reduced 8.41%	57,066 $163,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $51,927 - $78,987	-24,379 Reduced 28.12%	62,308 $181,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $65,675 - $151,629	23,044 Added 36.21%	86,687 $263,000
Q3 2021 Nov 09, 2021	BUY	$6.63 - $9.39 $86,932 - $123,121	13,112 Added 25.95%	63,643 $446,000
Q2 2021 Aug 13, 2021	SELL	$8.98 - $11.6 $124,085 - $160,288	-13,818 Reduced 21.47%	50,531 $463,000
Q1 2021 May 13, 2021	SELL	$9.38 - $13.63 $136,788 - $198,766	-14,583 Reduced 18.48%	64,349 $625,000
Q4 2020 Feb 11, 2021	SELL	$7.78 - $12.13 $181,141 - $282,422	-23,283 Reduced 22.78%	78,932 $810,000
Q3 2020 Nov 12, 2020	SELL	$9.5 - $11.14 $103,987 - $121,938	-10,946 Reduced 9.67%	102,215 $1.03 Million
Q2 2020 Aug 12, 2020	BUY	$7.01 - $13.24 $75,217 - $142,065	10,730 Added 10.48%	113,161 $1.18 Million
Q1 2020 May 13, 2020	BUY	$6.28 - $14.57 $78,493 - $182,110	12,499 Added 13.9%	102,431 $864,000
Q4 2019 Feb 10, 2020	SELL	$6.5 - $10.73 $29,529 - $48,746	-4,543 Reduced 4.81%	89,932 $787,000
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $301,393 - $442,618	34,445 Added 57.38%	94,475 $1.02 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $400,574 - $1.16 Million	32,567 Added 118.59%	60,030 $763,000
Q1 2019 May 15, 2019	BUY	$20.77 - $42.37 $4,237 - $8,643	204 Added 0.75%	27,463 $1.07 Million
Q4 2018 Feb 14, 2019	SELL	$20.07 - $46.7 $2.02 Million - $4.71 Million	-100,852 Reduced 78.72%	27,259 $555,000
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $4.85 Million - $7.04 Million	117,687 Added 1129.0%	128,111 $5.88 Million
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $177,116 - $250,272	-3,667 Reduced 26.02%	10,424 $616,000
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $2.72 Million - $4.53 Million	-45,614 Reduced 76.4%	14,091 $959,000
Q4 2017 Feb 14, 2018	SELL	$93.85 - $132.45 $12 Million - $16.9 Million	-127,844 Reduced 68.17%	59,705 $5.9 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $13.5 Million - $22.5 Million	187,549	187,549 $22.5 Million

Others Institutions Holding PBYI

# of Institutions

126

Shares Held

33.3M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $235M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account